Secondary prevention of acute venous thrombosis. Modern trends

Abstract

Venous thromboembolic complications (VTC) including deep veins thrombosis and pulmonary artery thromboembolia are sufficiently frequent but preventable states. In industrially developed countries 1-2 cases of VTC per 1 thousand persons per year are registered. In USA 900 thousand patients suffer from VTC annually. But these figures are most likely conservative as due to diffuseness of a clinical pattern and insufficient sensitivity of screening tests the frequency of verified VTC doesn't exceed 60-70% [1, 2].

Keywords

• венозные тромбоэмболические осложнения
• факторы риска
• антикоагулянтная терапия
• сулодексид
• venous thrombolic complications
• risk factors
• anticoagulant therapy
• sulodexide